002038.SZ
Beijing SL Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 6.37
−10.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 591.6M | 623.6M | 660.4M | 1.0B | 1.1B |
| Cost of Revenue | 217.1M | 236.1M | 211.5M | 187.8M | 157.0M |
| Gross Profit | 374.5M | 387.6M | 448.9M | 830.6M | 893.2M |
| Operating Expenses | |||||
| R&D Expense | 94.3M | 115.4M | 149.6M | 177.1M | 161.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 161.1M | 163.4M | 142.7M | 134.1M | 120.0M |
| Selling & Marketing Expense | 98.7M | 111.3M | 117.2M | 271.6M | 426.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 358.3M | 392.8M | 409.9M | 578.0M | 702.7M |
| Cost and Expenses | 575.4M | 628.9M | 621.4M | 765.8M | 859.7M |
| Operating Income (EBIT) | (431.4M) | (279.3M) | (119.6M) | 477.9M | 263.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (430.0M) | (278.1M) | (133.7M) | 464.9M | 259.4M |
| Income Tax Expense | 51.1M | 70.1M | (58.5M) | 49.9M | 31.0M |
| Bottom Line | |||||
| Net Income | (479.3M) | (347.2M) | (74.1M) | 416.7M | 234.4M |
| Earnings from Cont. Ops | (481.1M) | (348.2M) | (75.3M) | 415.0M | 228.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (479.3M) | (347.2M) | (74.1M) | 416.7M | 234.4M |
| Per Share | |||||
| Basic EPS | (CN¥0.46) | (CN¥0.34) | (CN¥0.07) | CN¥0.41 | CN¥0.23 |
| Diluted EPS | (CN¥0.46) | (CN¥0.34) | (CN¥0.07) | CN¥0.41 | CN¥0.23 |
| Revenue Per Share | CN¥0.55 | CN¥0.61 | CN¥0.62 | CN¥1.00 | CN¥1.03 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.0B | 1.1B | 1.0B | 1.0B |
| Diluted Shares Outstanding | 1.1B | 1.0B | 1.1B | 1.0B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | — | (112.2M) | 33.6M | 623.5M | 377.0M |
| D&A | — | 167.1M | 153.2M | 145.7M | 113.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026